de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, de Vogel-van den Bosch J, Kleerebezem M, Müller M, van der Meer R. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine.
THE INCIDENCE OF THE metabolic syndrome is increasing rapidly. Obesity and insulin resistance are considered the most important contributors to this syndrome and lipid accumulation in the liver is assumed to be the hepatic manifestation of the metabolic syndrome. Excessive intake of dietary fat is known to trigger the pathogenesis of the metabolic syndrome (3), but also type of dietary fat might have an effect. Human as well as animal studies have been performed to determine the effect of saturated, monounsaturated, and polyunsaturated fatty acids on parameters of metabolic syndrome; however, the results are not very consistent. Although several studies found a positive association between saturated fat and development of metabolic syndrome (7, 25) , other studies found no or even opposite effects of fat type (35) .
In the search for the underlying mechanisms that might explain the effects of diet on development of metabolic syndrome, so far the focus is mainly on liver, muscle, and white adipose tissue. However, there is growing evidence that also the small intestine can contribute significantly to the development of metabolic diseases, especially in diet-induced disorders (5, 16) . The small intestine is essential for digestion and absorption and is therefore the first interface between body and diet. Enterocytes of the small intestine can sense luminal contents and this can provoke changes in intestinal metabolism, which might lead to more global systemic effects. Moreover, diet can induce secretion of signaling molecules by the small intestine, such as gut hormones, to which liver, muscle, white adipose tissue, and brain can respond to sustain homeostatic control (6, 8, 14) . The role of gut microbiota in contributing to human health has increasingly been recognized, since several studies have shown that changes in microbial composition might be associated with the metabolic syndrome phenotype. Especially obesity is supposed to be linked to specific changes in gut microbiota, such as a reduced microbial diversity and an increased Firmicutes-to-Bacteroidetes ratio (19, 33) . Turnbaugh et al. (34) reported that an increased energy harvest from the diet by the obese microbiome plays a causal role in obesity, but this could not be confirmed in various other studies (18, 20) . Musso et al. (21) recently published an extensive overview of the potential interactions between gut microbiota and host metabolism in relation to the metabolic syndrome phenotype.
The first objective of our study was to investigate whether saturated fat has a more stimulatory effect on parameters of the metabolic syndrome than mono-and polyunsaturated fat. Therefore, C57Bl/6J mice were fed three different high-fat diets, rich in palm oil [polyunsaturated-to-saturated (P/S) ratio 0.4], olive oil (P/S ratio 1.1), and safflower oil (P/S ratio 7.8), for 8 wk. We analyzed the effect of these high-fat diets on weight gain, hepatic triglyceride accumulation, and insulin sensitivity. Next, we studied the hypothesis that fat-typeinduced differences in development of especially obesity could be linked to diet-induced compositional changes in gut microbiota. We analyzed gut microbiota composition in mice fed the different high-fat diets by using the recently developed Mouse Intestinal Tract (MIT) chip. Finally, we extensively analyzed fat-type-induced gene expression changes in the mucosa of the small intestine, to determine potential underlying mechanisms of dietary fat-induced metabolic disorders linked to the metabolic syndrome. So, in this study we explored fat-type-induced differences in development of obesity, hepatic steatosis, and insulin resistance and the potential contribution of the intestine.
MATERIALS AND METHODS

Animals and diets.
Male C57BL/6J mice were purchased from Harlan (Horst, The Netherlands) and were housed (2 per cage) in the light-and temperature-controlled animal facility of Wageningen University. They had free access to water and prior to the diet intervention they received standard laboratory chow (RMH-B, Arie Blok, Woerden, The Netherlands) for 3 wk, followed by a low-fat diet based on palm oil (LF-PO; fat content 10% of energy) for 3 wk to adapt to purified diets. All experiments were submitted to and approved by the Local Committee for Care and Use of Laboratory Animals at Wageningen University. The experiments were performed under their license.
After the adaptation period, 9-wk-old mice were maintained on the LF-PO (reference) diet or received purified high-fat diets (fat content 45% of energy) varying in saturated, monounsaturated, and polyunsaturated fatty acids for 8 wk. The high-fat diets were based on palm oil (HF-PO; P/S 0.4), olive oil (HF-OO; P/S 1.1), or safflower oil (HF-SO; P/S 7.8). The powdered diets were composed by Research Diet Services (Wijk bij Duurstede, The Netherlands), and their complete composition is given in Table 1 . During diet intervention body weight was recorded weekly. To determine diet-induced changes at an early and late time point during diet intervention, six mice per diet group were euthanized after 2 and 8 wk, in the postprandial state. Diurnal variability was avoided by harvesting tissues at the same time of the day for all diet groups. Prior to the euthanasia, mice were anesthetized with isoflurane (1.5% in 70% nitrous oxide-30% oxygen). The small intestines were excised and the adhering fat and pancreatic tissue were carefully removed. The small intestines were divided into three equal parts along the proximal-to-distal axis (proximal, middle, and distal parts of small intestine) and small intestinal mucosal cells were scraped. Mucosal scrapings and liver tissues were snap frozen in liquid nitrogen and stored at Ϫ80°C. At week 2, mice that were not euthanized were fasted for 6 h to collect fasting plasma samples. Fasting and fed blood samples were collected in EDTAcontaining microtubes (Sarstedt, Nümbrecht, Germany). Plasma was obtained after centrifugation at 11,000 g for 10 min and frozen at Ϫ80°C. An oral glucose tolerance test (OGTT) was performed after 7 wk of diet intervention. Therefore, after a 6-h fast, six mice per diet group received 0.5 ml of a 20% glucose solution via an oral gavage and blood glucose was measured after 15, 30, 45, 60, 90, and 150 min via Accu-Chek blood glucose meters (Roche Diagnostics, Almere, The Netherlands). We chose week 7 for the OGTT to avoid that this test would interfere with diet-induced changes in intestine and liver that were studied at the end of the diet intervention (week 8). Food intake was determined by supplementing the diets with nonabsorbable chromic oxide for 1 wk (week 5 of diet intervention). At the end of this week feces was quantitatively collected during 48 h and fecal chromic oxide levels were determined as previously described (28) . These fecal chromic oxide levels were then used to calculate the energy intake per mouse per day. The 5-wk time point was chosen because it did not interfere with other tests within the diet intervention study.
Liver triglyceride content. Liver triglycerides were measured with a commercially available kit from Instruchemie (Delfzijl, The Netherlands). In short, livers were weighed and homogenized in a buffer (pH 7.5) containing 250 mM sucrose, 2 mM EDTA, and 10 mM Tris, with a final tissue concentration of 10%, and 2 l of liver homogenate was used to determine triglyceride content.
Fecal and plasma analyses. After 5 wk of diet intervention, feces were collected, lyophilized, weighed, and homogenized. Using the CAL2k Isothermal Bomb Calorimeter (CAL2k, Johannesburg, Gauteng, South Africa), we analyzed total fecal energy. Total free fatty acids in feces were determined as described previously (10) . For this, appropriate standards and reference samples were assayed simultaneously. The recovery of added standards always exceeded 95%. The absorption of dietary energy and fat was calculated by subtracting the fecal amounts excreted per day from the daily intake.
Plasma insulin levels were detected by the Insulin (Mouse) Ultrasensitive EIA (Alpco Diagnostics, Salem, NH). Plasma glucose levels were determined by using Accu-Chek blood glucose meters (Roche Diagnostics).
Fecal microbiota analysis. Feces were collected after 5 wk of diet intervention. Fecal samples of four mice (pooled per two) were analyzed by using a phylogenetic microarray, called MITChip (Mouse Intestinal Tract Chip) (9) , designed in analogy to the human array (HITChip) (24) , that comprises 3,580 probes targeting 1,885 murine phylotypes. Samples were processed as follows: in short, bacterial DNA was isolated with the recently described DNA extraction from Salonen et al. (26) using 0.1 g of fecal samples from each diet. The full-length 16S rRNA gene was amplified by using primers T7prom-Bact-27-for and Uni-1492-rev. The PCR products were transcribed into RNA and the resultant RNA was labeled with Cy3 and Cy5 prior to fragmentation and hybridization to the array. Microarray analyses were conducted by using the MITChip produced by Agilent Technologies (Palo Alto, CA) as described earlier (24) . Arrays were scanned with Agilent DNA Microarray Scanner to collect fluorescence data, which were then extracted from the generated images by using the Agilent Extraction Software 9.1. The array normalization was done as described earlier (24) . The (pre) processing was performed using in-house MySQL and R scripts. The diversity of the microbial community assessed by MITChip analysis was expressed as Simpson's reciprocal index of diversity (1/D) that was calculated by using the equation ϭ 1/ΑP i^2 where Pi is the proportion of the i th taxon. RNA isolation. Total RNA was isolated by using TRIzol reagent (Invitrogen, Breda, The Netherlands) according to the manufacturer's instructions. The isolated RNA was further column purified by using the SV total RNA isolation system (Promega, Leiden, The Netherlands). RNA concentration was measured on a NanoDrop ND-1000 UV-Vis spectrophotometer (Isogen, Maarssen, The Netherlands) and analyzed on a bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands) with 6000 Nano Chips according to the manufacturer's instructions.
Microarray hybridization and analysis. For each part of small intestine, total RNA was pooled per diet group (n ϭ 6). RNA was hybridized to Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA). Detailed methods for the labeling and subsequent hybridizations to the arrays are described in the eukaryotic section in the GeneChip Expression Analysis Technical Manual Rev. 3 from Affymetrix, which is available upon request. Arrays were scanned on an Affymetrix GeneChip Scanner 3000. Data analysis was performed in MAS 5.0, which is also provided by Affymetrix. To estimate the magnitude and direction of differential gene expression, MAS 5.0 software provides signal log ratios (SLR). If the SLR is equal to or greater than 0, fold change is obtained with 2 (Signal Log Ratio) , otherwise (Ϫ1)ϫ2 Ϫ(Signal Log Ratio) . On the basis of perfect match and mismatch probes, MAS 5.0 software also calculates the significance of differential gene expression. Array data have been submitted to the Gene Expression Omnibus, accession number GSE18586. Dendrogram results were obtained by performing the Quality Control Pipeline analysis of the MadMax database using gcRMA normalization (https://madmax.bioinformatics.nl).
cDNA synthesis and real-time quantitative PCR. Single-stranded complementary DNA (cDNA) was synthesized from 1 g of total RNA by using the reverse transcription system (Promega, Leiden) following the supplier's protocol. cDNA was amplified on a Bio-Rad CFX384 Real-Time System using Sensimix (Bioline; GC Biotech, Alphen aan de Rijn, The Netherlands). Mouse (m) and human (h) primer sequences used for real-time quantitative PCR (qPCR) were chosen on the basis of the sequences available in the GenBank database (www.ncbi.nlm.nih.gov): mAngptl4 (5=-CACCAATGTTTCCCCCAAT-3=,5=-CACGGAGGT-CATGGTCTTG-3=), mFabp1 (5=-AAAGGAAACCTCATTGC-CACCA-3=,5=-AATGTCGCCCAATGTCATGGTA-3=), mScd1 (5=-CCGGAGACCCTTAGATCGA-3=,5=-TAGCCTGTAAAAGATTTCT-GCAAACC-3=), mBcmo1 (5=-CATCCCCGACTTCACAGACAA-3=,5=-GGGGTCGATTTTCCTGATGTAG-3=), mMttp (5=-ATACAAG-CTCACGTACTCCACT-3=,5=-TCCACAGTAACACAACGTCCA-3=), hAngptl4 (5=-CACAGCCTGCAGACACAACTC-3=,5=-GGAGGC-CAAACTGGCTTTGC-3=), hAcaa2 (5=-CTGCTCCGAGGTGTGTTT-GTA-3=,5=-GCAGCAAATTCAGACAAGTCAGT-3=), hSlc25a20 (5=-GCATCACGGGGCTATATCGG-3=,5=-CTTCTGGGTGTTTCTGTT-GTAGT-3=). The following thermal cycling conditions were used: 8 min at 94°C, followed by 45 cycles of 94°C for 15 s and 60°C for 1 min. PCR reactions were performed in duplicate and all samples were normalized to cyclophilin A expression (m: 5=-TGTCTTTGGAACTTTGTCTGCAA-3=,5=-CAGACGCCACTGTCGCTTT-3=; h: 5=-AGGATAGCTTAAC-CCTGACTTTGG-3=,5=-TCTTTGGGACCTTGTCTGCAA-3=).
Cell culture and fatty acid incubation. LS174T cells were cultured in DMEM with 10% FBS, 1% penicillin-streptomycin solution, and 1% minimal essential medium with nonessential amino acids (MEM NEAA) (all from Lonza Bioscience, Verviers, Belgium). Cells were incubated at 37°C, 5% CO 2, and 95% humidity. For the fatty acid incubation experiment, cells were maintained in serum-free medium that contained 11 g/l fatty acid free BSA and was supplemented with 500 M fatty acids (palmitic acid C16:0, oleic acid C18:1, and linoleic acid C18:2; Sigma-Aldrich, Zwijndrecht, the Netherlands). Before adding to the cells, fatty acids were bound to BSA by preincubation in the BSA-containing medium for 30 min at 37°C. A 
RESULTS
Energy and fat absorption. To determine the effect of different types of high-fat diet with varying saturated and mono-and polyunsaturated fatty acid content on development of metabolic syndrome, C57Bl/6J mice were fed a reference diet (LF-PO) and three different types of high-fat diet, based on palm oil (HF-PO; P/S 0.4), olive oil (HF-OO; P/S 1.1), and safflower oil (HF-SO; P/S 7.8) for 8 wk. Table 2 shows that we found no significant differences in energy intake and fecal energy loss between the diets. However, because of a slightly lower intake and higher fecal loss of energy, net energy absorption was lowest on the HF-PO diet. Next, we calculated daily fat absorption. As expected we found that mice on the LF-PO diet showed a significantly lower absolute fat absorption than mice fed the high-fat diets (Table 2) . Moreover, we found a significant higher fat absorption in mice fed the HF-SO diet compared with the HF-PO diet. Although we found no significant differences between the HF-PO and HF-OO diet, also here the fat absorption on the HF-PO diet tended to be slightly lower. Together our data indicate that mice fed the HF-PO diet have a (slightly) lower energy and fat absorption than mice fed the HF-OO and HF-SO diets.
Body weight gain, liver triglyceride content, and insulin sensitivity. Next, we studied the effect of fat type on development of obesity, fatty liver, and insulin resistance, which are three metabolic parameters that are highly associated with the metabolic syndrome phenotype. We analyzed weight gain, liver triglyceride content, and insulin sensitivity during diet intervention. We found a significant higher body weight gain on the HF-PO diet compared with the LF-PO diet throughout the 8 wk of diet intervention (Fig. 1) . Mice on the HF-OO diet became significantly more obese than mice on the LF-PO diet after 4 wk of diet intervention, and no significant differences in weight gain were found between mice fed the HF-SO and LF-PO diet. Surprisingly, mice fed the HF-PO diet had a higher weight gain than mice fed the HF-SO and HF-OO diet, despite the lower fat/energy absorption on the HF-PO diet, described above. The significant correlation (r ϭ 0.84, P Ͻ 0.01) that we found between epididymal fat pad weight and body weight gain (Fig. 2) indicates that the higher body weight gain on the HF-PO diet is associated with an expansion of white adipose tissue. We also found significant higher liver triglyceride levels in mice fed the HF-PO diet than in mice fed the HF-OO, HF-SO, and LF-PO diets. Liver triglyceride levels on the HF-OO and HF-SO diets were highly similar or even lower than in control mice (Table 3) . Insulin sensitivity was evaluated by calculating the homeostasis model assessment of insulin resistance (HOMA-IR) index (week 2) and performing an OGTT (week 7). For the HOMA-IR index, we found significant higher values, meaning lower insulin sensitivity, in mice fed the HF-PO diet compared with mice on the LF-PO and HF-SO diets. For the HF-OO diet, also a tendency for a better insulin sensitivity was found, but the difference with the HF-PO diet was not significant (P ϭ 0.08). Interestingly, we found that the fat-type-induced differences in HOMA-IR index were mainly due to differences in plasma insulin levels between the high-fat diets (HF-PO 9.9 Ϯ 1.4 U/ml, HF-OO 7.2 Ϯ 1.2 U/ml, HF-SO 5.2 Ϯ 0.6 U/ml). After 7 wk of diet intervention, the OGTT revealed that mice on the LF-PO diet showed a better glucose tolerance than mice on the HF-PO diet (Table 3) . However, no significant differences were found between the different high-fat diets. Taken together, our data show that the HF-PO diet has the most stimulatory effect on development of various metabolic disorders related to metabolic syndrome in C57BL/6J mice, especially on obesity and hepatic steatosis. Diet-induced changes in gut microbiota composition. Several studies have suggested that changes in gut microbiota, especially a reduction in microbial diversity, a decrease of Bacteroidetes and an elevation of Firmicutes are correlated with (development of) obesity (19, 33, 34) . Therefore, we studied whether fat-type-induced changes in weight gain are associated with compositional changes in the gut microbiota. In mice fed the LF-PO, HF-PO, HF-OO, and HF-SO diets, we determined diet-induced compositional changes by analyzing 16S rRNA of fecal microbiota using a phylogenetic microarray, the so-called MITChip. Hierarchical clustering of the MITChip data showed that the HF-PO diet clustered separate from the other diets (Fig. 3A) . Figure 3B shows a reduction of microbial diversity on the HF-PO diet as was measured by Simpson index (30) . Moreover, focusing on the relative microbiota composition, we found that the most pronounced difference between the HF-PO diet and the other diets was an elevated Firmicutes-to-Bacteroidetes ratio (Fig. 3C and Table 4 ). The analyzed Firmicutes phylum included Bacilli and Clostridium clusters of which especially Clostridium clusters XI, XVII, and XVIII were relatively higher in quantity on the HF-PO diet. Microbial composition induced by the HF-OO and HF-SO diets showed no significant differences with the LF-PO diet, except for the very low level of Deferribacteres, which was different between all diets.
Since not only mice on the HF-PO diet but also mice fed the HF-OO diet are significantly more obese than mice on the LF-PO diet ( Fig. 1 ) and no significant differences were found in gut microbiota composition between the HF-OO and LF-PO diets, our data do not confirm the previously proposed causality between obesity and an altered microbial composition. Since we only found differences in gut microbiota composition on a HF-PO diet, we hypothesize that these microbial differences are not directly and exclusively associated with the obese phenotype but are mainly induced by a more pronounced overflow of dietary fat to distal parts of the intestine. This is supported by the fact that mice on the HF-PO diet showed the highest fecal fat content (Table 2) .
Diet-induced gene expression changes in the distal small intestine.
To verify the potential overflow of the HF-PO diet to the more distal parts of the intestine, as is indicated by our MITChip data, we analyzed diet-induced gene expression changes along the longitudinal axis of the small intestine (proximal, middle, and distal small intestine). Therefore, we performed microarray analysis on intestinal samples that were collected after 2 wk of diet intervention. Again the LF-PO diet was taken as a reference. Hierarchical clustering of our microarray data showed that in the proximal and middle part of the small intestine, the high-fat diets clustered separate from the LF-PO diet (Fig. 4A) . This indicates that in these parts of the small intestine the amount of dietary fat is the most prominent factor to distinguish diet-induced gene expression profiles. In the distal part of the small intestine, we found that the HF-PO diet clustered separate and thus distinguished itself from all the other diets. To explore whether gene expression profiles reflect the hypothesized overflow of dietary fat on the HF-PO diet to the distal intestine, we analyzed differential gene expression in the distal small intestine in more detail. By performing comparison analyses, we found that 751, 385, and 443 genes were differentially expressed on the HF-PO, HF-OO, and HF-SO diets compared with the LF-PO diet, respectively. This indicates that the HF-PO diet induced the highest number of changes in gene expression in the distal small intestine. Furthermore, the Venn diagram in Fig. 4B shows that the overlap of differentially expressed genes induced by the different high-fat diets is relatively small. Next, we focused on lipid metabolism-related differentially expressed genes (based on Gene Ontology Biological Process annotation) (heat maps in Fig. 4B ). We found that the HF-PO diet had the most pronounced effect on lipid metabolism in the Visualized is the relative contribution of sum of hybridization signal obtained for probes targeting 25 phylogenetic groups (levels 1 ϭ Class/Clostridium clusters). Letters in superscript indicate significant differences between the diets calculated by a 1-way ANOVA with Bonferroni posttest (P Ͻ 0.05):
a HF-PO diet significantly different from HF-OO, HF-SO and LF-PO diet.
b HF-OO diet significantly different from HF-SO diet. c All diets are significantly different from each other. distal small intestine, because it induced the highest number of lipid metabolism-related differentially expressed genes (n ϭ 69). Most of these differentially expressed genes were upregulated by the HF-PO diet and showed no or an opposite regulation by the other high-fat diets. Only seven lipid metabolism-related genes showed a similar differential expression for all high-fat diets. Most lipid metabolism-related genes that were specifically changed by the HF-OO and/or HF-SO diet showed a downregulated expression. Additionally, we noticed that ϳ40% of the lipid metabolism-related genes were target genes of peroxisome proliferator-activated receptor alpha (Ppar␣), a nuclear receptor that regulates gene transcription upon activation by fatty acids (in italics in Fig. 4B ). Together these microarray data support the proposed overflow of dietary fat to the distal small intestine on a HF-PO diet.
To ascertain that the saturated fat-induced overflow to the distal intestine is still present after prolonged diet intervention, the ileal expression of five randomly selected lipid metabolismrelated genes was analyzed by qPCR, after 8 wk of diet intervention (Fig. 5) . By comparing gene expression levels on the control LF-PO diet with levels on the high-fat diets, as was previously also done in our microarray analysis, we again found a significant upregulation of fatty acid binding protein 1 (Fabp1), stearoyl-coenzyme A desaturase 1 (Scd1), and microsomal triglyceride transfer protein (Mttp) on the HF-PO diet and no or an opposite differential expression on the HF-OO and HF-SO diets. The differential expression that was found for angiopoietin-like protein 4 (Angptl4) and beta-carotene 15,15=-monooxygenase 1 (Bcmo1) after 2 wk of diet intervention was not significant anymore after prolonged diet intervention. Additionally, for these genes the expression on the HF-OO diet was now in between expression on the HF-PO and HF-SO diets. Interestingly, this fits the profiles found for obesity and hepatic lipid accumulation after 8 wk of diet intervention. For Fabp1, Scd1, and Mttp the expression levels were still significantly higher on the HF-PO diet compared with the HF-OO and HF-SO diets, for which the expression levels were quite similar. So, even though differential gene expression of Angptl4 and Bcmo1 seems to be less pronounced after 8 wk of diet intervention, in general our qPCR data indicate that there is still an increased overflow of dietary fat to the distal small intestine on the HF-PO diet compared with the other diets.
Our gene expression data of small intestines exposed 2 and 8 wk to a high-fat diet revealed a higher expression of lipid metabolism-related Ppar␣ target genes on the saturated fat diet (HF-PO) compared with the more unsaturated fat diets (HF-OO and HF-SO). This is surprising, because it is commonly known that unsaturated fatty acids are the better stimulators of Ppar␣. To determine whether saturated fatty acids also can stimulate the expression of Ppar␣ target genes, we incubated the intestinal LS174T cell line with saturated (C16:0, palmitic acid), monounsaturated (C18:1, oleic acid), and polyunsaturated (C18:2, linoleic acid) fatty acids for 6 h (Fig. 6) . Although the changes in gene expression were somehow variable between the selected lipid metabolism-related genes, in general all fatty acids induced an upregulation of gene expression compared with the control. In our in vivo study, however, we found that only the HF-PO diet induced an upregulation of lipid metabolism-related genes in the distal small intestine. This must then be due to a higher amount of fat that reaches the distal small intestine on the HF-PO diet compared with the HF-OO and HF-SO diets.
DISCUSSION
This study shows that a high-fat diet rich in saturated fat (HF-PO) has a more stimulatory effect on development of obesity and hepatic steatosis than more unsaturated high-fat diets (HF-OO and HF-SO). The effects of saturated fat on insulin sensitivity seemed to be less clear, since the OGTT after 7 wk of diet intervention showed no significant differences between the high-fat diets. However, our OGTT results are in accordance with OGTT results that were previously reported by Lee et al. (17) . Despite the lack of differences in plasma glucose levels, they found that significantly higher levels of plasma insulin were required during the OGTT on a high-saturated fat diet compared with a high-polyunsaturated fat diet to establish a comparable blood glucose clearance. Similar to our HOMA-IR index findings, these data suggest that fat type has a primarily effect on plasma insulin levels, which might consequently lead to alterations in glucose homeostasis.
On the basis of our data, we conclude that the stimulating effect of saturated fat on development of obesity and hepatic steatosis cannot be directly explained by an increased energy or fat absorption on the HF-PO diet, as if anything, mice on the HF-PO diet had an even slightly lower absorption than mice on the HF-OO and HF-SO diets (Table 2 ). Our data indicate that a difference in energy dissipation rather than a difference in energy absorption must explain the HF-PO diet-induced development of obesity. Potential energy-dissipating mechanisms known to be regulated by different types of dietary fat are thermogenesis, especially in brown adipose tissue, and lipogenesis in liver and white adipose tissue. Both these energy dissipating processes are previously reported to be less induced by saturated fatty acids than by unsaturated fatty acids (29, 31) .
In contrast to our study, many studies report that C57BL/6J mice become hyperphagic on the high-fat diet. In these studies, the low-fat and high-fat diets are administered to the mice in pellet form. However, low-fat diet pellets (D12450B, Research Diets) have a much denser structure than high-fat diet pellets (D12451, Research Diets). A previous diet intervention study that we performed revealed that this difference in pellet hardness of the low-fat and high-fat diets plays a substantial role in the hyperphagia that is commonly seen in C57Bl/6J mice (N. de Wit and R. van der Meer, unpublished data). Moreover, it has to be noted that the resulting higher energy intake on the pelleted high-fat diet is likely to provide an additional, but confounding stimulus to the development of obesity in C57BL/6J mice, next to the sole dietary fat effect. Therefore, we have chosen to use only powdered diets in our present intervention study.
Differential mucosal gene expression after 2 and 8 wk of diet intervention together with our in vitro gene expression results clearly indicate that on a HF-PO diet the overflow of dietary fat to the distal intestine is more pronounced than on the LF-PO, HF-OO, and HF-SO diets. These potential higher amounts of fatty acids in the distal intestine on the HF-PO diet might induce an antimicrobial effect on the gut microbiota (15) , leading to the reduction in bacterial diversity and changes in the Firmicutes-to-Bacteroidetes ratio that we found on the HF-PO diet. Hildebrandt et al. (13) also described a lowering of bacterial sequences after consumption of a high-fat diet rich in saturated fatty acids. Previous studies have suggested a direct link between gut microbiota composition and obesity (1, 19, 34) , but it is still unclear whether this association is dependent on diet. From our data we conclude that the microbial changes in the intestine cannot be directly and exclusively associated with weight gain, since particularly the microbial profile induced by the HF-OO diet does not correlate with the obese phenotype. These data suggest that diet, in our case type and amount of dietary fat, has a more direct effect on gut microbiota composition than obesity itself. This is in accordance with recent studies that stress the importance of diet as a primary determinant of gut microbiota composition (13, 20) . Our data strongly indicate that especially an overflow of diet to distal parts of the intestine has a substantial effect on the composition of gut microbiota. This novel finding is an essential factor to keep in mind when studying causal relationships between gut microbiota compositional changes in association with certain diet-induced diseases.
Nevertheless, we cannot exclude the possibility that changes in gut microbiota composition, primarily induced by diet, can subsequently contribute to development and/or progression of metabolic disorders. Recently, the potential mechanisms , and linoleic acid (C18:2) for 6 h. Gene expression of lipid metabolism-related Ppar␣ target genes was determined by qPCR analysis. Data are visualized as the mean expression of triplicates Ϯ SE, relative to the control, which was set to 1. *Significant differential gene expression (Student's t-test; P Ͻ 0.05) compared with the control. whereby microbiota can influence host metabolism are extensively reviewed by Musso et al. (21) and Greiner and Backhed (11) . For instance, it is suggested that gut microbiota are potentially involved in regulation of energy expenditure and fat storage (1, 32) . Additionally, modulations in the bile acid enterohepatic cycle by bacterial deconjugation and dehydroxylation of primary bile acids might influence lipid absorption and other lipid metabolism-related processes. Several genes, such as Angptl4 (also called fasting-induced adipose factor, Fiaf) (1), peptide YY (Pyy) (27) , adenosine monophosphateactivated protein kinase (Ampk) (2), Toll-like receptor 5 (Tlr5) (36), G-protein coupled receptors Gpr41 and Gpr43 (4), and farnesoid X receptor (Fxr) are described to have a potential role in these processes. For all these genes we found no differential gene expression between the diets in the distal small intestine (data not shown). Only Angptl4 showed a higher expression on the HF-PO diet compared with the other diets, but this would contradict Backhed et al.'s (1) hypothesis that Angptl4 suppresses fat storage. However, in our study it is hard to link diet-induced intestinal differential gene expression to dietinduced compositional changes in gut microbiota, since the intestinal mucosa used for transcriptomic analysis and fecal samples for bacterial composition analysis are isolated from different parts of the intestine (small intestine and colon, respectively).
In our study, an overflow of dietary fat to the distal parts of the intestine on the HF-PO diet was supported by diet-induced differential expression of lipid metabolism-related genes in the distal small intestine after 2 and 8 wk of diet intervention. For most lipid metabolism-related genes, we found that the expression on the LF-PO diet was in between expression levels on a HF-PO diet and the other high-fat diets or at the same level as on the HF-OO and HF-SO diets. This indicates that the LF-PO diet induces an even more pronounced overflow of dietary fat to the distal parts of the intestine than the high-fat diets rich in olive oil and safflower oil. This suggests that palm oil, rich in saturated fat, is the main trigger for extension of fat absorption to the distal parts of the small intestine.
Whether and how the increased lipid handling in the distal small intestine on the HF-PO diet might be related to development of obesity and fatty liver remains unclear. However, some of the lipid metabolism-related genes that are regulated on the HF-PO diet, such as Bcmo1 and Scd1 were previously already associated with metabolic syndrome. Hessel et al. (12) reported that Bcmo1-null mice are more prone to development of obesity than wild-type mice. Moreover, these Bcmo1-null mice showed a drastic accumulation of triglycerides in liver on a high-fat diet. In our study, we found a downregulation of Bcmo1 on the HF-PO diet in proximal, middle (data not shown), and distal small intestine. This intestinal decrease in Bcmo1 levels might affect intestinal lipid handling and contribute to the increased weight gain and elevated hepatic triglyceride levels that we found on the HF-PO diet. After 8 wk of diet intervention, we found that Bcmo1 levels on a HF-OO diet were decreasing and getting closer to the gene expression levels on the HF-PO diet. This might reflect the changed profiles for obesity and hepatic lipid accumulation, as also for these characteristics the HF-OO and HF-PO diet became closer after prolonged diet intervention. We also found an upregulation of Scd1 on the HF-PO diet compared with the HF-OO and HF-SO diets. This seems logical, since Scd1 is the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids and saturated fats are its main substrate. However, recent studies showed that Scd1 is also a component of the metabolic response of leptin signaling, it upregulates insulin-signaling components, and it affects glycogen metabolism (23) . Additionally, Ntambi et al. (22) showed that Scd1-null mice are protected from development of obesity when fed a high-fat diet. On the basis of these previous results, we speculate that the intestinal upregulation of Scd1 on the HF-PO diet might contribute to the higher weight gain that we found on this diet. In conclusion, our diet intervention study in C57Bl/6J mice indicates that the saturated fat diet (HF-PO) induces the development of obesity and hepatic steatosis to a higher degree than the unsaturated fat diets (HF-OO and HF-SO). Furthermore, we showed that a diet high in saturated fat induces an overflow of dietary fat to the distal parts of the intestine. This is most likely the primary trigger to induce changes in gut microbiota composition. These diet-induced changes in gut microbiota composition can then subsequently contribute to development and/or progression of metabolic disorders linked to the metabolic syndrome. Additionally, the overflow of dietary fat to the distal small intestine may also contribute to obesity and hepatic steatosis via changes in especially lipid metabolism-related genes that were previously already associated with the etiology of the metabolic syndrome.
